Skip to main content
. 2023 Mar 6;15(3):856. doi: 10.3390/pharmaceutics15030856

Figure 1.

Figure 1

Anti-tumour efficiency of pHSV-TK-VCMBs with FUS. (A) Quantitative results of HSV-TK expression after using pHSV-TK-VCMBs and FUS treatment (N = 4 per group, compared with untreated group). (B) T2-weighted MRI images of brain tumours at 4, 11, 18, and 25 days after tumour implantation. Rats received no treatment (control group) or treatment on day 7 with: direct injection, pHSV-TK-CMBs, or pHSV-TK-VCMBs. (C) Tumour volume assessed by MRI imaging (N = 6 per group, compared with untreated group). (D) Analysis of animal survival rate (N = 6 per group, compared with untreated group) (* p < 0.5, ** p < 0.01). Reprinted with permission from Ref. [165], Elsevier, copyright 2014.